 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12...4567891011121314...2223» |
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Trial completion, Trial completion date, Trial primary completion date, Surgery: Comparison of Recovery Profiles Among Propofol, Remimazolam, and Dexmedetomidine After Intraoperative Sedation (clinicaltrials.gov) - Jan 31, 2024
P4, N=120, Completed, Sponsor: Asan Medical Center
Not yet recruiting --> Completed | Trial completion date: Dec 2023 --> Aug 2023 | Trial primary completion date: Dec 2023 --> Aug 2023
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Trial initiation date, Head-to-Head: Remimazolam vs. Propofol: Impact on Postoperative Delirium in Neurosurgical Patients (clinicaltrials.gov) - Jan 28, 2024
P=N/A, N=696, Not yet recruiting, Sponsor: Samsung Medical Center
Not yet recruiting --> Completed | Trial completion date: Dec 2023 --> Aug 2023 | Trial primary completion date: Dec 2023 --> Aug 2023 Initiation date: Nov 2023 --> Feb 2024
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal, Surgery: General Anesthesia With Remimazolam During Minimally Invasive Cardiac Surgery for Atrial Septal Defect: A Pediatric Case Report. (Pubmed Central) - Jan 27, 2024
The patient awoke and was extubated promptly after surgery, without any serious adverse events, including intraoperative awareness. Remimazolam may be a viable option for general anesthesia during pediatric cardiac surgery.
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal, Surgery: Effect of Remimazolam on Pain Perception and Opioid-Induced Hyperalgesia in Patients Undergoing Laparoscopic Urologic Surgery-A Prospective, Randomized, Controlled Study. (Pubmed Central) - Jan 27, 2024
Group RHR, which received remimazolam, attenuated OIH, including mechanically evoked pain and some clinically relevant pain outcomes caused by a high dose of remifentanil. Further research is essential to determine how clinically meaningful and important the small differences observed between the two groups are.
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Retrospective data, Journal, Surgery: Effect of acute normovolemic hemodilution in patients undergoing cardiac surgery with remimazolam anesthesia. (Pubmed Central) - Jan 25, 2024
In patients undergoing CPB, ANH reduced intraoperative transfusion amount and postoperative bleeding. Hemodynamic changes during blood collection were minimal under remimazolam anesthesia and high-volume ANH was feasible.
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New trial: Comparison of Remimazolam-based MAC With Inhalation General Anesthesia Under the Guidance of an ANI Monitor During TURB (clinicaltrials.gov) - Jan 22, 2024
P=N/A, N=46, Not yet recruiting, Sponsor: Yonsei University
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New P4 trial: CEDCRSA: Comparison of Emergence Delirium: Remimazolam vs Sevoflurane Anesthesia (clinicaltrials.gov) - Jan 19, 2024
P4, N=90, Not yet recruiting, Sponsor: Second Affiliated Hospital of Wenzhou Medical University
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Trial completion date, Trial initiation date, Trial primary completion date: Comparison of Procedural Sedation in TEE (clinicaltrials.gov) - Jan 19, 2024
P1, N=120, Not yet recruiting, Sponsor: University of Alabama at Birmingham
Hemodynamic changes during blood collection were minimal under remimazolam anesthesia and high-volume ANH was feasible. Trial completion date: Jun 2024 --> Dec 2024 | Initiation date: Jan 2024 --> Apr 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Enrollment open: Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients (clinicaltrials.gov) - Jan 18, 2024
P=N/A, N=400, Recruiting, Sponsor: Tianjin Medical University General Hospital
Trial completion date: Jun 2024 --> Dec 2024 | Initiation date: Jan 2024 --> Apr 2024 | Trial primary completion date: Jun 2024 --> Sep 2024 Not yet recruiting --> Recruiting
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal: Remimazolam attenuates inflammation in bronchopneumonia through the inhibition of NLRP3 activity by PDPK1 ubiquitination. (Pubmed Central) - Jan 17, 2024
Not yet recruiting --> Recruiting Remimazolam increased the expressions of PDPK1 and p-AKT in
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal, Head-to-Head: Effect of remimazolam vs propofol on emergence from general anesthesia in patients undergoing cerebral endovascular procedures: A randomized controlled, non-inferiority trial. (Pubmed Central) - Jan 15, 2024
Remimazolam increased the expressions of PDPK1 and p-AKT in In patients undergoing cerebral endovascular procedures, remimazolam did not increase the time from anesthesia vs propofol.
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal: Electroencephalographic features of elderly patients during anesthesia induction with remimazolam: a sub-study of a randomized controlled trial. (Pubmed Central) - Jan 11, 2024
In patients undergoing cerebral endovascular procedures, remimazolam did not increase the time from anesthesia vs propofol. Both regimens showed a greater decrease in feedback connectivity compared to a decrease in feedforward connectivity after loss of consciousness, leading to a disruption of asymmetry between the frontoparietal connectivity.
- || ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Clinical, Journal, Head-to-Head, Surgery: Effect of remimazolam on electroencephalogram burst suppression in elderly patients undergoing cardiac surgery: Protocol for a randomized controlled noninferiority trial. (Pubmed Central) - Jan 9, 2024
This noninferiority trial is the first to evaluate the effect of perioperative remimazolam administration on EEG burst suppression, POD occurrence, and duration of hypotension in elderly patients who undergo cardiac surgery. Chinese Clinical Trial Registry (ChiCTR2200056353).
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma, ciprofol injectable emulsion (HSK3486) / Haisco
Journal: Dreaming during gastrointestinal endoscopy under propofol, ciprofol, or remimazolam anesthesia: study protocol for a parallel-design double-blind, single-center trial. (Pubmed Central) - Jan 8, 2024
This study may observe different incidences of dreaming and diverse types of dreams, which might lead to different evaluations to the anesthesia procedure. Based on the coming results, anesthesiologists can make a better medication plan for patients who are going to undergo painless diagnosis and treatment.
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal, Surgery: Application of remimazolam transversus abdominis plane block in gastrointestinal tumor surgery. (Pubmed Central) - Jan 4, 2024
Based on the coming results, anesthesiologists can make a better medication plan for patients who are going to undergo painless diagnosis and treatment. The application effect of TAPB combined with remimazolam general anesthesia in anesthesia of patients undergoing gastrointestinal tumor surgery is good, which is helpful to promote faster recovery after operation.
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New trial: RP: The Effects of Remimazolam on the Incidence of Severe Hypoxia During Sedated Hysteroscopy for Assisted Reproduction in Overweight or Obese Patients (clinicaltrials.gov) - Jan 3, 2024
P=N/A, N=600, Not yet recruiting, Sponsor: RenJi Hospital
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Trial completion date, Trial initiation date, Trial primary completion date: Comparison of Procedural Sedation in TEE (clinicaltrials.gov) - Dec 31, 2023
P1, N=120, Not yet recruiting, Sponsor: University of Alabama at Birmingham
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal, Surgery: Editorial: Pediatric anesthesia and surgery: prophylaxis, managements, and rehabilitation of short-term and long-term complications of CNS during perioperative period. (Pubmed Central) - Dec 25, 2023
The application effect of TAPB combined with remimazolam general anesthesia in anesthesia of patients undergoing gastrointestinal tumor surgery is good, which is helpful to promote faster recovery after operation. No abstract available
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal, Head-to-Head: Finding the ideal sedative: a non-inferiority study of remimazolam vs propofol in endoscopic retrograde cholangiopancreatography. (Pubmed Central) - Dec 25, 2023
Incidences of adverse events were comparable. Remimazolam is a safe and effective alternative to propofol for ERCP sedation, expanding options for clinicians and improving patient outcomes.
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New trial: EEG Parameters Between Remimazolam- and Propofol-based Anesthesia (clinicaltrials.gov) - Dec 21, 2023
P=N/A, N=60, Completed, Sponsor: Yonsei University
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal, Surgery: Efficacy and safety of remimazolam compared with propofol in hypertensive patients undergoing breast cancer surgery: a single-center, randomized, controlled study. (Pubmed Central) - Dec 17, 2023
Remimazolam is safe and effective in hypertensive patients undergoing breast cancer surgery. Induction with remimazolam in hypertensive patients may result in more stable hemodynamics than propofol.
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New trial: DRIP: Dose of Remimazolam in Children for Intubation (clinicaltrials.gov) - Dec 14, 2023
P=N/A, N=40, Not yet recruiting, Sponsor: Zhihong LU
- || ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Enrollment open: PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function (clinicaltrials.gov) - Dec 13, 2023
P2, N=36, Recruiting, Sponsor: Wuhan Union Hospital, China
Induction with remimazolam in hypertensive patients may result in more stable hemodynamics than propofol. Not yet recruiting --> Recruiting
- || ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Retrospective data, Review, Journal: Comparison of Remimazolam-Flumazenil versus Propofol for Recovery from General Anesthesia: A Systematic Review and Meta-Analysis. (Pubmed Central) - Dec 9, 2023
However, it is important to consider the higher risk of re-sedation when using this combination in clinical practice. Due to limitations in the quality of the evidence, it is advisable to interpret the results of meta-analyses with caution.
- ||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal, Adverse events: Remimazolam Pilot for Office-Based Dental Sedation: Adverse Events, Awareness and Outcomes. (Pubmed Central) - Dec 9, 2023
These findings suggest that in a limited cohort, the remimazolam-alfentanil regimen appears to be well tolerated and effective for office-based dental procedures in adult patients, with a low risk of adverse events, acceptable hemodynamic effects, rapid onset and recovery and minimal intraoperative awareness. This study provides valuable insights into the potential use of the remimazolam-alfentanil combination in dental sedation practice.
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal: Incidence of intraoperative hypotension in older patients undergoing total intravenous anesthesia by remimazolam versus propofol: A randomized controlled trial. (Pubmed Central) - Dec 9, 2023
This study provides valuable insights into the potential use of the remimazolam-alfentanil combination in dental sedation practice. Total intravenous anesthesia with remimazolam was associated with less intraoperative hypotension than propofol in older patients, with a comparable recovery profile.
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Trial completion, Enrollment change: Comparison of Remimazolam and Propofol Effect on Oxygenation Reservoir During Diagnostic Gastric Endoscopy (clinicaltrials.gov) - Dec 8, 2023
P=N/A, N=70, Completed, Sponsor: Yonsei University
Total intravenous anesthesia with remimazolam was associated with less intraoperative hypotension than propofol in older patients, with a comparable recovery profile. Not yet recruiting --> Completed | N=40 --> 70
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Trial initiation date, Surgery: Remimazolam for Cataract Surgery (clinicaltrials.gov) - Dec 6, 2023
P4, N=120, Not yet recruiting, Sponsor: University of California, Los Angeles
Not yet recruiting --> Completed | N=40 --> 70 Initiation date: Sep 2023 --> Jan 2024
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New trial: Safety and efficacy of remimazolam compared with dexmedetomidine for sedation in patients with end-stage renal disease (EUDRACT) - Dec 5, 2023
P=N/A, N=80, Not yet recruiting, Sponsor: Department of Anesthesiology, West China Hospital of Sichuan University; West China Hospital of Sichuan University
Initiation date: Sep 2023 --> Jan 2024 .
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New trial: Application of Remimazolam combined with Goal-Directed Fluid Therapy in elderly patients undergoing hip surgery: A randomized controlled trial (EUDRACT) - Dec 5, 2023
P=N/A, N=60, Not yet recruiting, Sponsor: Chaohu Hospital of Anhui Medical University; Chaohu Hospital of Anhui Medical University
. .
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New trial: The influence of preoperative anxiety on remimazolam EC50 for the body movement during dilating cervix in hysteroscopy (EUDRACT) - Dec 5, 2023
P=N/A, N=60, Recruiting, Sponsor: Shunde Hospital of Southern Medical University; Shunde Hospital of Southern Medical University
. .
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New trial: Clinical study on remimazolam besylate for induction and maintenance of anesthesia in children (EUDRACT) - Dec 5, 2023
P=N/A, N=200, Not yet recruiting, Sponsor: Yichang Central People's Hospital; Yichang Central People's Hospital
. .
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New trial: The effectiveness and safety of remimazolam besylate for sedation in patients at risk of gastrointestinal bleeding: A single-center prospective randomized controlled study comparing with propofol. (EUDRACT) - Dec 5, 2023
P=N/A, N=80, Not yet recruiting, Sponsor: The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital; Yichang Central People's Hospital
. .
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New trial: Comparison of the efficacy of remimazolam and propofol in the treatment of restlessness in children with awakening (EUDRACT) - Dec 5, 2023
P=N/A, N=120, Recruiting, Sponsor: Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Qiaokou District, Wuhan City, Hubei Province; T
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New trial: Effect of remimazolam total intravenous general anesthesia on emergence agitation in children undergoing laparoscopic surgery (EUDRACT) - Dec 5, 2023
P=N/A, N=180, Recruiting, Sponsor: Affiliated Bo'ai Hospital of Zhongshan, Southern Medical University; Affiliated Bo'ai Hospital of Zhongshan, Southern Medical University
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New P4 trial: Effect of remimazolam combined with flumazenil on quality of resuscitation and recovery after painless abortion (EUDRACT) - Dec 5, 2023
P4, N=60, Recruiting, Sponsor: Ningbo Zhenhai District Traditional Chinese Medicine Hospital; Ningbo Zhenhai District Traditional Chinese Medicine Hospital
. .
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New P4 trial: Remimazolam for the prevention of emergence agitation in adult following nasal surgery under general anesthesia: a randomized controlled study (EUDRACT) - Dec 5, 2023
P4, N=86, Recruiting, Sponsor: Lishui People's Hospital; Lishui People's Hospital
. .
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New P4 trial: Comparison of the effects of propofol-based and remimazolam-based total intravenous anesthesia on sleep quality in patients undergoing ambulatory gastroenteroscopic polypectomy: a prospective, randomized controlled study (EUDRACT) - Dec 5, 2023
P4, N=234, Not yet recruiting, Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New P4 trial: A multicenter prospective randomized controlled study of remimazolam besylate for sedation in patients on mechanical ventilation after cardiac surgery (EUDRACT) - Dec 5, 2023
P4, N=318, Recruiting, Sponsor: Cardiothoracic surgery ICU of the First Affiliated Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Sun Yat-Sen University
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New P4 trial: Effect of remazolam on root canal recovery in children under combined anesthesia (EUDRACT) - Dec 5, 2023
P4, N=126, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University; East Branch of the First Affiliated Hospital of Zhengzhou University
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New P4 trial: Randomized controlled trial of the efficacy and safety of the remimazolam besylate for gastroenteroscopy sedation in patients with suspected sleep apnea (EUDRACT) - Dec 5, 2023
P4, N=80, Recruiting, Sponsor: The first affiliated hospital of Fujian Medical University, China.; The first affiliated hospital of Fujian Medical University, China.
. .
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New P4 trial: Individualized medication of remimazolam and its influencing factors under total intravenous anesthesia (EUDRACT) - Dec 5, 2023
P4, N=300, Recruiting, Sponsor: The First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New P4 trial: Median effective dose of remimazolam for procedural sedation under brachial plexus block in young and middle-aged patients (EUDRACT) - Dec 5, 2023
P4, N=40, Not yet recruiting, Sponsor: Yanan University Affiliated Hospital; Yanan University Affiliated Hospital
. .
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma, ciprofol injectable emulsion (HSK3486) / Haisco, Sufenta (sufentanil) / Akorn
New P4 trial: Comparison of remimazolam, ciprofol and propofol plus sufentanil in endoscopic diagnosis and treatment, respectively (EUDRACT) - Dec 5, 2023
P4, N=138, Recruiting, Sponsor: The Affiliated Hospital of Guizhou Medical University; The Affiliated Hospital of Guizhou Medical University
. .
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New P4 trial: Efficacy of remimazolam besylate versus propofol plus remifentanil for maintenance of anesthesia in elderly patients: a randomized controlled trial (EUDRACT) - Dec 5, 2023
P4, N=450, Not yet recruiting, Sponsor: Deyang People's Hospital; Deyang People's Hospital
. .
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New P4 trial: Efficacy and safety evaluation of remimazolam in children receiving dental treatment (EUDRACT) - Dec 5, 2023
P4, N=320, Not yet recruiting, Sponsor: The Third Affiliated Hospital of Air Force Medical University; The Third Affiliated Hospital of Air Force Medical University
. .
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New P4 trial: Comparison of adverse events with different infusion rates of remimazolam during sedation gastroscopy: a randomized controlled trial (EUDRACT) - Dec 5, 2023
P4, N=309, Recruiting, Sponsor: Weinan Central Hospital; Weinan Central Hospital
. .
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma, ciprofol injectable emulsion (HSK3486) / Haisco
New P4 trial: Comparative study on the antianxiety effect of remimazolam besylate and ciprofol after hysteroscopy (EUDRACT) - Dec 5, 2023
P4, N=80, Recruiting, Sponsor: Mengcheng County No. 1 People's Hospital; Mengcheng County No. 1 People's Hospital
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma, Sufenta (sufentanil) / Akorn
New P4 trial: Effect of propofol or different doses of remimazolam on median effective dose of sufentanil for suppressing tracheal intubation response in elderly patients (EUDRACT) - Dec 5, 2023
P4, N=120, Not yet recruiting, Sponsor: the Second Hospital of Jiaxing; the Second Hospital of Jiaxing
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New P4 trial: Study on remimazolam for general anesthesia in geriatric orthopedic surgery (EUDRACT) - Dec 5, 2023
P4, N=240, Not yet recruiting, Sponsor: Xi'an International Medical Center Hospital; Xi'an International Medical Center Hospital